Associated Papers
Population-specific putative causal variants shape quantitative traits.
Koyama S et al.
Nature Genetics, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.
Venkatachalapathy P et al.
Pharmacogenomics and Personalized Medicine, 2021
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P et al.
Pharmaceutical Research, 2018
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
Lozano E et al.
Journal of Personalized Medicine, 2018
Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine.
Choi CI et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2013
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H et al.
The Aaps Journal, 2013
Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients.
Zhang J et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
Li Q et al.
Acta Pharmacologica Sinica, 2010
Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver.
Shin HJ et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML et al.
Pharmacogenetics and Genomics, 2010
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML et al.
Diabetes, 2009
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.
Avery P et al.
Pharmacogenomics and Personalized Medicine, 2009
Genetic variants of the organic cation transporter 2 influence the disposition of metformin.
Song IS et al.
Clinical Pharmacology and Therapeutics, 2008
Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population.
Kang HJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.
Fujita T et al.
Journal of Pharmaceutical Sciences, 2006
Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2).
Fukushima-Uesaka H et al.
Drug Metabolism and Pharmacokinetics, 2004